Researchers at the Salk Institute have developed a patient-derived organoid platform to study chronic pancreatitis, a condition affecting approximately three million people worldwide for which no cure currently exists. By generating 37 organoids from patients, the study—published in Cell Stem Cell—identified cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction as a key therapeutic target and uncovered three distinct biological subtypes of the disease.
Modeling Chronic Pancreatitis Through Patient-Derived Organoids
Over the last decade, organoids have become a prevalent tool to bridge the gap between cell and human studies. The Salk Institute team, led by assistant professor Dannielle Engle, addressed this by creating miniature, lab-grown replicas of the pancreas using stem or progenitor cells taken directly from patients. According to the study, this method preserves the unique, patient-specific disease biology.
“By growing organoids directly from patients, we preserve key features of ductal cells and ask which disease mechanisms are active in each individual patient,” said Victoria Osorio-Vasquez, a postdoctoral researcher in Engle’s lab and the study’s first author. This approach allows scientists to move beyond a “one-size-fits-all” clinical diagnosis and instead analyze the specific molecular drivers causing inflammation in an individual.
Did you know? Organoids function as “mini-organs” that allow researchers to test how specific human tissues react to drugs before they are ever administered to a patient in a clinical trial.
CFTR Dysfunction as a Therapeutic Target
The research revealed that approximately half of the organoids tested exhibited dysfunctional CFTR proteins. Crucially, this dysfunction was present even in patients who did not carry the inherited genetic mutations typically associated with cystic fibrosis. This suggests that current genetic screening methods may miss a significant number of patients who could potentially benefit from existing therapies.
The team tested clinically available CFTR modulators—drugs already approved for cystic fibrosis—on the organoids. The results showed that these modulators were capable of stabilizing or restoring CFTR function and reducing inflammatory signaling in the responsive samples. This finding identifies a potential “repurposing” pathway for existing medications to treat chronic pancreatitis patients who share similar molecular signatures.
The Future of Personalized Pancreatic Medicine
Beyond CFTR, the organoid platform identified rare alterations to the KRAS and TP53 genes. These findings provide a new lens through which researchers can examine the progression of chronic inflammation and its link to pancreatic cancer risk. By studying these genetic changes at the interface of disease, scientists hope to develop better biomarkers for early detection.
“Our platform enables a more personalized way of studying and eventually treating chronic pancreatitis, while also blazing the trail for other organoid-based platforms in other inflammatory disease contexts,” Engle said.
Frequently Asked Questions
What is an organoid?
An organoid is a miniature, three-dimensional tissue culture grown from stem cells that replicates the structure and function of a specific human organ, such as the pancreas.
Can cystic fibrosis drugs treat chronic pancreatitis?
According to the Salk Institute study, CFTR modulators may stabilize function and reduce inflammation in a subset of chronic pancreatitis patients who show CFTR dysfunction, even if they do not have a cystic fibrosis diagnosis.
Why is personalized medicine important for this condition?
Patients often share the same clinical diagnosis of chronic pancreatitis while possessing very different underlying molecular drivers. Personalized organoid models allow doctors to identify which specific biological mechanism is active in an individual, leading to more tailored and effective therapies.
Are you interested in the latest developments in personalized medicine? Subscribe to our weekly research newsletter to stay updated on how organoid technology is changing the future of clinical care.